Sign In
Buy RARE
$33.22
-0.600 (-1.77%)
At Close: Jul 13, 2026
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
09:08am, Wednesday, 08'th Jul 2026
NOVATO, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) released its 2025 Impact Report, detailing the company's work on behalf of patients and families living
Ultragenyx (RARE) Soars 5.2%: Is Further Upside Left in the Stock?
11:16am, Monday, 29'th Jun 2026
Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase
Ultragenyx: The Setrusumab Reset Creates A Cleaner Rare Disease Opportunity
11:43am, Sunday, 21'st Jun 2026
Ultragenyx (RARE) is transitioning from a broad pipeline to a focused rare disease platform, entering a high-catalyst period with four approved products and multiple late-stage assets. Despite a recen
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 19'th Jun 2026
NOVATO, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
07:32pm, Tuesday, 09'th Jun 2026
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm
04:36pm, Thursday, 04'th Jun 2026
NEW YORK, June 4, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) brea
Ultragenyx (RARE) Down 13.6% Since Last Earnings Report: Can It Rebound?
12:35pm, Thursday, 04'th Jun 2026
Ultragenyx (RARE) reported earnings 30 days ago. What's next for the stock?
Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference
04:30pm, Wednesday, 03'rd Jun 2026
NOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser
AMGEN TO PRESENT NEW DATA ACROSS RARE AUTOIMMUNE AND INFLAMMATORY DISEASES AT EULAR 2026
09:00am, Wednesday, 03'rd Jun 2026
New Phase 3 MITIGATE Open-Label Extension Data Support the Long-Term Safety Profile and Sustained Results of UPLIZNA ® in IgG4-RD Real-World Evidence Supports TAVNEOS ® Efficacy and Safety Profile w
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm
12:09pm, Tuesday, 02'nd Jun 2026
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)
Kuehn Law Encourages Investors of Ultragenyx Pharmaceutical Inc. to Contact Law Firm
05:50pm, Monday, 01'st Jun 2026
New York, New York--(Newsfile Corp. - June 1, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NAS
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 22'nd May 2026
NOVATO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
10:20pm, Tuesday, 12'th May 2026
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Rare disease families find roadmap to drug development at bootcamps
06:30am, Thursday, 07'th May 2026
Rare disease families are increasingly driving research efforts to find treatments for their children. Ultragenyx's Rare Bootcamp gives advocates a roadmap for navigating drug development.
Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference
04:30pm, Wednesday, 06'th May 2026
NOVATO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for seri
